Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial - Gerstein, H C; Colhoun, H M; Dagenais, G R (Lancet, 2019)
. doi:10.1016/s0140-6736(19)31149-3